Elmind Capital’s Krystal Biotech KRYS Stock Holding History

Elmind Capital’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.18M	Hold	22,000	–	–	2.05%	15
2026 Q1	$5.68M	Hold	22,000	–	–	1.61%	18
2025 Q4	$5.42M	Buy	+22,000	New	+$4.63M	1.6%	17

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Elmind Capital's KRYS Position: Q2 2026 in Review

Elmind Capital held its Krystal Biotech (KRYS) position steady in Q2 2026 at 22,000 shares worth $8.18M. The position accounts for 2.05% of the portfolio, ranked #15.

Elmind Capital first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Elmind Capital held 22,000 shares of Krystal Biotech worth $8.18M as of Q2 2026.
Elmind Capital left its Krystal Biotech share count unchanged in Q2 2026.
Krystal Biotech made up 2.05% of Elmind Capital's portfolio in Q2 2026, its #15 holding.
Elmind Capital first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.